ERBB2 and triple-negative breast carcinoma: The meta-analysis of breast cancer demographics in Indian patients by Sandhu et al1 highlights significant variability in estrogen receptor (ER)/progesterone receptor (PR)/human epidermal growth factor receptor 2 (HER2) status and presenting age reported by various authors and then pools the data to ascertain the rate of triple-negative breast cancer (TNBC) to be around 31%.